TMTPOST – Chai Discovery, an AI-driven biotech startup founded just six months ago, has secured nearly $30 million in funding from OpenAI and Thrive Capital. The startup is focused on using artificial intelligence to revolutionize drug development. Chai Discovery’s AI models are designed to predict the structure of biochemical molecules and reprogram their interactions, a critical step in drug discovery. “Our goal is to transform biology from a science into an engineering discipline,” said Joshua Meier, co-founder and CEO of Chai Discovery. The company’s innovative approach could potentially accelerate the process of developing new medicines.